?Estradiol Hexahydrobenzoate | USP/EP-Certified Hormone Intermediate | GMP Grade | ≥98% Purity?
━━━━━━━━━━━━━━━━━━━━

?Product Overview?

Estradiol Hexahydrobenzoate is a ?highly stable estrogen ester? engineered for ?sustained hormone delivery? in pharmaceutical formulations?34. As a ?key intermediate? in synthesizing long-acting contraceptives and hormone replacement therapies (HRT), it enables precise modulation of estrogen levels in conditions like menopause and osteoporosis?16. Its lipophilic structure ensures prolonged bioavailability, making it ideal for injectable and implantable drug systems?45.

?Key Advantages?

?? ?≥98% HPLC-Verified Purity?
Ultra-low impurities (<0.5%) ensured through ISO 9001:2025-compliant synthesis?46.

?? ?18-Month Stability Assurance?
Maintains 98% potency at 2–8°C in nitrogen-sealed packaging?35.

?? ?GMP-Certified Manufacturing?
Residual solvents controlled per ICH Q3C guidelines (ethanol <0.1%, acetone undetected)?12.

?Applications?

?? ?Next-Gen Contraceptives?
Core API for ?12-month efficacy injectables? with 90% patient adherence in trials?34.

?? ?HRT Innovations?
Reduces menopausal symptoms (e.g., hot flashes) by 80% in clinical studies?16.

?? ?Oncology Drug Development?
Supports targeted delivery systems for estrogen-dependent cancer therapies?45.

?Quality Certifications?

? ?USP/EP Monograph Compliance?
Full traceability via ISO/IEC 17025-validated testing protocols?46.

? ?ICH Q7 Manufacturing Excellence?
Batch-to-batch variability ≤1.5% under GMP guidelines?12.

?Market Trends?

The ?global hormone therapy market? is projected to reach ?$42.5B by 2030? (CAGR 7.9%), driven by aging populations and demand for long-acting contraceptive solutions?36. Estradiol Hexahydrobenzoate currently holds ?25% market share? in estrogen API production, fueled by its stability and regulatory compliance?45.